Neurology
Narcolepsy Comorbidities and Their Symptom Profiles: What Clinicians and Patients Should Know
Narcolepsy is a chronic neurological sleep disorder that rarely exists alone.
Dr. Abu Bakar · 6 min read
The archive
All stories
392 stories, newest first — page 10 of 17.
Latest briefs
Neurology
Big Ideas from the 2026 American Academy of Neurology Annual Meeting (AAN): What’s Changing in Brain Health and Why It Matters
As in previous years the Annual Meeting of the American Academy of Neurology (AAN) was a large convention
Rayan Salih · 13 min read
Neurology
Wrap-Up: Vyvgart Targets Four Populations at AAN 2026
A Summary of the 2026 AAN Annual Meeting for Rare Diseases from a Managed Care Perspective – Myasthenia
Rayan Salih · 9 min read
Neurology
Vyvgart Hytrulo Challenges the Step Therapy Model in Treatment-Naive CIDP
ADHERE post hoc data at AAN 2026 show 87.5% of treatment-naive CIDP patients respond early to Vyvgart Hytrulo, challenging IVIG step therapy.
Rayan Salih · 7 min read
Neurology
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
ADAPT Jr data show 80% of adolescent gMG patients achieved minimal symptom expression by cycle two with efgartigimod at AAN 2026.
Rayan Salih · 7 min read
Innovation & Devices
Pixee Wins FDA Nod For Next-Gen AR Knee Surgery Tech
Pixee Medical’s newly cleared Knee+ NexSight brings augmented reality (AR) into total knee arthroplasty (TKA) in the U.S.
Rayan Salih · 7 min read
Oncology
Sunvozertinib Shows Promising First-Line PFS Benefit in EGFR Exon 20 Insertion NSCLC
Sunvozertinib is drawing attention because early reports suggest it may offer progression-free survival benefit as a first-line treatment
Dr. Abu Bakar · 8 min read
Endocrinology & Metabolism
Bridging the Gap: Understanding CMS’ Delay of the BALANCE Model and the Extension of the GLP-1 Bridge
The Trump administration has formally announced a delay of the Medicare Part D implementation of the Center for
Rayan Salih · 13 min read
Neurology
The New Frontier in Neurological Research: Are GLP-1s Changing the Game?
Research to treat Alzheimer’s and other neurodegenerative diseases has been largely focused on removal of amyloid-beta plaques and
Rayan Salih · 10 min read
Neurology
Ocular Myasthenia Gravis Gets Its First Targeted Biologic Candidate
Phase 3 ADAPT OCULUS data at AAN 2026 show efgartigimod significantly improves ocular MG symptoms, supporting a planned FDA sBLA submission for the oMG indication.
Rayan Salih · 2 min read
Oncology
Sexual Health After Cancer: Why Survivorship Care Must Include Intimacy and Recovery
Sexual health after cancer is often overlooked, yet it is a major part of survivorship care.
Dr. Abu Bakar · 8 min read
Oncology
Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact
For patients with neoadjuvant HER2+ breast cancer, clinicians are increasingly reconsidering whether carboplatin a platinum chemotherapy drug sometimes
Dr. Abu Bakar · 7 min read
Neurology
Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis
Phase 3 ADAPT SERON data at AAN 2026 show efgartigimod significantly improves MG-ADL scores in seronegative gMG patients, with FDA priority review targeting May 10, 2026.
Rayan Salih · 8 min read
Oncology
FDA Approves Pylarify TruVu to Expand PSMA-PET Imaging Access for Prostate Cancer
The Food and Drug Administration has approved the use of Pylarify TruVu, which is an updated version of
Dr. Abu Bakar · 8 min read
Neurology
Low‑Dose Lithium for Mild Cognitive Impairment: What a Pilot Trial Shows About Safety and Feasibility
An early trial of the method involving lithium treatment in people with mild cognitive impairment (MCI) revealed that
Dr. Abu Bakar · 7 min read
Oncology
T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing
Trastuzumab Deruxtecan (T-DXd) is now increasingly emerging as the preferred choice for HER2-low metastatic breast cancer patients, and
Dr. Abu Bakar · 9 min read
Oncology
The Gap Between Cancer Treatment And Survivorship Support
Many people go through cancer treatment and assume that they will return to life’s “new normal,” only to
Dr. Abu Bakar · 7 min read
Oncology
Ultra‑Hypofractionated Radiation Therapy for Locally Advanced Breast Cancer
Shorter, higher‑dose radiation therapy schedules are being explored for people with locally advanced breast cancer, and early experience
Dr. Abu Bakar · 6 min read
Oncology
Matched Sibling Donors Remain the Gold Standard for PTCy‑Based Allogeneic Stem Cell Transplantation
Matched sibling donors remain the top choice for allogeneic hematopoietic cell transplantation (allo-HCT) using post-transplant cyclophosphamide (PTCy) ,
Dr. Abu Bakar · 7 min read
Health Policy
Accountable Care Org Savings: Hard To Measure, Hard To Find
Accountable Care Organization (ACO) savings are central to a decade‑long experiment in paying differently for Medicare care.
Rayan Salih · 7 min read
Innovation & Devices
MiniMed 780G Pump Secures CE Mark With Abbott Instinct Sensor
The MiniMed 780G, an automated insulin delivery system from Abbott, has received FDA clearance to work with the
Rayan Salih · 10 min read
Infectious Disease
MHC Class I On Target Cells Regulates CD4+ T-Cell Immunity
A fundamental shift in our understanding of the Major Histocompatibility Complex (MHC) Class I function on target cells
Rayan Salih · 11 min read
Neurology
FDA Approves Avlayah In Hunter Syndrome Neurologic Manifestations
The U.S. Food and Drug Administration today approved Avlayah (tividenofusp alfa-eknm) for the management of central neurologic manifestations
Rayan Salih · 10 min read
Health Policy
State Spending Growth Benchmarks & Hospital Revenue
Health care spending is the fastest growing component of state budgets as well as of employer sponsored health
Rayan Salih · 11 min read